about
Mephedrone and nicotine: oxidative stress and behavioral interactions in animal modelsCould selenium administration alleviate the disturbances of blood parameters caused by lithium administration in rats?The Influence of Lithium and/or Selenium Treatment on Homeostasis of Chosen Bioelements in Rats.[Role of matrix metalloproteinases in the pathogenesis of multiple sclerosis].The genetic predisposition and its impact on the diabetes mellitus development in patients with alcoholic chronic pancreatitis.Matrix Metalloproteinase-9 (MMP-9) Gene Polymorphism in Stroke Patients.Worse Neurological State During Acute Ischemic Stroke is Associated with a Decrease in Serum Albumin LevelsSimvastatin Effect on Calcium and Silicon Plasma Levels in Postmenopausal Women with Osteoarthritis.The Influence of Manganese and Glutamine Intake on Antioxidants and Neurotransmitter Amino Acids Levels in Rats' Brain.Homeostasis of chosen bioelements in organs of rats receiving lithium and/or seleniumXanthohumol inhibits the extracellular signal regulated kinase (ERK) signalling pathway and suppresses cell growth of lung adenocarcinoma cells.Does Vitamin C Influence Neurodegenerative Diseases and Psychiatric Disorders?Matrix Metalloproteinases as a Pleiotropic Biomarker in Medicine and Biology.Correlation between CH2DS2-VASc Score and Serum Leptin Levels in Cardioembolic Stroke Patients: The Impact of Metabolic Syndrome.Is There Any Relationship between Plasma 25-Hydroxyvitamin D₃, Adipokine Profiles and Excessive Body Weight in Type 2 Diabetic Patients?Matrix metalloproteinase-9 contributes to the increase of tau protein in serum during acute ischemic stroke.Thrombolytic treatment decreases glutamate/GABA ratio in serum during acute ischaemic stroke: a pilot study.Does serum Tau protein predict the outcome of patients with ischemic stroke?Serum bilirubin and uric acid levels as the bad prognostic factors in the ischemic stroke.The rtPA increases MMP-9 activity in serum during ischaemic stroke.The effect of recombinant tissue plasminogen activator on MMP-2 and MMP-9 activities in vitro.Decreased nitric oxide serum level after pituitary adenoma resection.Different patterns of gelatinolytic activity in pituitary macro- and microadenomas.Neurofilament ELISA validation.[The novel views on the patomechanism of ischemic stroke].Antioxidant Potential of Propolis, Bee Pollen, and Royal Jelly: Possible Medical Application.Xenobiotics, Oxidative Stress, and Antioxidants.Acute MDMA and Nicotine Co-administration: Behavioral Effects and Oxidative Stress Processes in MiceThe decrease of serum MMP-2 activity corresponds to alcoholic cirrhosis stageSimvastatin could prevent increase of the serum MMP-9/TIMP-1 ratio in acute ischaemic strokeThe effect of interferon beta-1a on MMP-2 and MMP-9 proteolytic activityThymectomy as an effective treatment in myastheniaGelatinolytic activity of matrix metalloproteinases 2 and 9 in middle ear cholesteatoma[Matrix metalloproteinases and atherosclerosis][Processes of free radical lipid peroxidation with a particular regard to the role of paraoxonase-1 in the pathogenesis of multiple sclerosis]Humoral response against glial derived antigens in Parkinson's diseaseAntioxidative mechanism in the course of varicose veinsActylise treatment does not influence nitric oxide metabolites serum level
P50
Q28393490-B85E144D-CBB2-481F-948A-34E12141CB93Q33574522-C117EC5D-10A1-4A02-B4E7-203DA77F9E68Q33840926-CBC671C6-3343-4804-BC1B-438D8CA5F547Q34555464-F5896E19-3292-4FBF-B2EE-C212C936DD74Q35206902-F6EC466C-C5B8-4C5E-A1C3-6D587A5A5F14Q36275092-3DDA2711-306F-4633-8911-C994F37EAA0EQ36792508-66EB511D-A2CA-41B5-8E54-3D9076092F40Q36798923-9AF3D45B-46B4-48F7-83A5-4795FBEEDB2EQ37099332-D7A7FE1C-A628-4F38-90CE-6F2AEF6C6CBEQ37277456-B916F198-9A34-409C-9B12-EC895ECB07A8Q38763708-4F0658BB-DFE1-4A88-B558-2B81FA323AC2Q39400501-E7D72A29-A069-443C-BDB2-5878F8B0704BQ42364466-A5E2A1CF-25FE-423D-8B1C-1E09773A9584Q46703877-4248C3C4-9584-4429-A357-FAFD78368C67Q47172465-435C993F-12F6-4957-A4A9-8E7C3C2AE7DAQ48129246-5A9B031F-DF08-408A-A800-118459DDE0D6Q48161641-B140BB98-CB43-404E-AB0C-5C67E458C6E6Q48165350-8515B945-2B80-4669-900F-C190114CD248Q48406432-1A0A8771-E30C-4DA2-B38C-EB629245933DQ48441296-37DF4138-2086-4B35-A3EB-BA7C5EEC8A70Q48696369-0323DDE0-78CD-42EB-A87C-708354E6BA14Q49850930-03C27CB8-F299-40A2-86C7-97F8880D34CFQ51004104-F2B25846-DA40-43D0-9247-9A06A042F615Q53061482-8A25C8E1-ACB1-4CB6-B4C0-AA251710E325Q53285837-B3606031-79DD-4CF6-AFC8-D9992F72DB73Q55042760-806407D7-F1E9-4057-9147-2AFB2F08A222Q55353856-373C47F2-829D-4C94-BBDC-34B799171229Q58803432-458ED6FB-7520-4520-9B47-D0511204947BQ59484803-D083CE3C-C61A-4F6E-A2D8-68486E9F3A09Q79447127-8CE09EB7-37D5-4E58-BE1C-1201A5321C29Q80173572-E30E81FA-4CAA-4A46-A0A1-AC172CE2F2EDQ81173761-4BE59C3F-33E4-4B0E-9C6D-2ACF98872918Q83156585-308EF75A-A578-4B57-8B39-7F519D2F39A1Q83491655-F3EFB4A1-8E04-47EB-BB99-C090487C6AFCQ84663135-2EC3FA72-1475-4750-9919-0F4430949AC8Q87401028-1AC723CF-6882-4109-8125-26C95560B77BQ88512258-F2BF3256-899F-4F99-8B8A-55BF0DD67402Q95561386-D7D8D175-F044-4C39-AECD-4A5A742D61C5
P50
description
researcher ORCID ID = 0000-0002-7524-8831
@en
wetenschapper
@nl
name
Jacek Kurzepa
@ast
Jacek Kurzepa
@en
Jacek Kurzepa
@es
Jacek Kurzepa
@nl
type
label
Jacek Kurzepa
@ast
Jacek Kurzepa
@en
Jacek Kurzepa
@es
Jacek Kurzepa
@nl
prefLabel
Jacek Kurzepa
@ast
Jacek Kurzepa
@en
Jacek Kurzepa
@es
Jacek Kurzepa
@nl
P106
P21
P31
P496
0000-0002-7524-8831